Cargando…

Toward a glycopeptide-based HIV-1 vaccine

Detalles Bibliográficos
Autores principales:	Wang, Lai-Xi, Li, Bing, Li, Hengguang, Wang, Jinsong
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716988/ http://dx.doi.org/10.1186/1742-4690-3-S1-S75

Ejemplares similares

Attacking latent HIV: towards eradication of HIV infection
por: Margolis, DM
Publicado: (2006)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Any progress for HIV vaccines to come?
por: Wigzell, Hans
Publicado: (2006)

Towards a multi-antigen multi-stage malaria vaccine
por: Hill, Adrian VS, et al.
Publicado: (2014)

OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers
por: Vasan, S, et al.
Publicado: (2009)

Vaccination of HIV positive children... a genuine challenge
por: Vlad, Delia Adelina, et al.
Publicado: (2013)

Elite control of HIV infection: implications for vaccines
por: Pereyra, Florencia, et al.
Publicado: (2006)

HLA-A*0201-specific epitopes of Indian HIV-1C as candidates for vaccine design
por: Sundaramurthi, Jagadish Chandrabose, et al.
Publicado: (2012)

Novel strategy for generation of mucosal immune responses against HIV-1 following systemic vaccination
por: Kutzler, Michele A, et al.
Publicado: (2006)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

OA031-03. Increased regulatory T cell frequency and HIV-1 specific suppression after therapeutic vaccination of HIV-infected patients on antiretroviral therapy
por: Macatangay, BC, et al.
Publicado: (2009)

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
por: Rolland, M, et al.
Publicado: (2009)

Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules
por: Gatignol, A, et al.
Publicado: (2014)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
por: Krachmarov, C, et al.
Publicado: (2012)

OA021-03. Design and development of DNA vaccines for the co-expression of micro-RNA and HIV-1 Env
por: Wheatley, AK, et al.
Publicado: (2009)

Towards a patient-based drug discovery
por: Schreiber, Stuart L
Publicado: (2012)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Long-term protection of hepatitis B vaccine in HIV-infected patients
por: Biekre, R, et al.
Publicado: (2014)

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine
por: Cai, Hui, et al.
Publicado: (2018)

Chemoenzymatic Synthesis and Antibody Binding of HIV-1 V1/V2 Glycopeptide-Bacteriophage Qβ Conjugates as a Vaccine Candidate
por: Zong, Guanghui, et al.
Publicado: (2021)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Vaccine responses to conserved regions of the HIV-1 proteome are associated with an increased capacity to inhibit multiple virus isolates ex vivo
por: Ashraf, A, et al.
Publicado: (2012)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali
por: Poole, D, et al.
Publicado: (2012)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies
por: Amin, Mohammed N., et al.
Publicado: (2013)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
por: Jackson, AG, et al.
Publicado: (2012)

Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer
por: Mao, Youdong, et al.
Publicado: (2013)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

Design of lipid nanoparticle delivery agents for multivalent display of recombinant Env trimers in HIV vaccination
por: Pejawar-Gaddy, S, et al.
Publicado: (2012)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

HIV-1 Tat and T cell apoptosis
por: Krammer, Peter H
Publicado: (2006)

From XMRV to HIV-1 and back
por: Coffin, John M
Publicado: (2011)

RNAi strategies to silence HIV-1
por: Eekels, Julia, et al.
Publicado: (2011)

Molecular diversity of HIV-1 in Croatia
por: Grgic, Ivana, et al.
Publicado: (2014)

Regulation of HIV-1 gene expression
por: Benkirane, Monsef
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8rmfkac8mgopi4nlk98otja4vb